Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bertino

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
ESMO Open|March 11, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutationsL C Villaruz, X Wang, E M Bertino, et al.
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Cancer Immunology, Immunotherapy : CII|July 31, 2020
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancerMingjia Li, Daniel Spakowicz, Songzhu Zhao, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2021
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survivalTyler C Haddad, Songzhu Zhao, Mingjia Li, et al.
Journal of Cancer Research and Clinical Oncology|September 7, 2022
Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survivalAbdul Miah, Gabriel Tinoco, Songzhu Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Pancreas|April 18, 2013
Consensus guidelines for the management and treatment of neuroendocrine tumorsPamela L Kunz, Diane Reidy-Lagunes, Lowell B Anthony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or LeptomeningesLaura Q M Chow, Fabrice Barlesi, Erin M Bertino, et al.
The Journal of Biological Chemistry|April 10, 1999
Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion moleculesC W Rittershaus, L J Thomas, D P Miller, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
ESMO Open|March 11, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutationsL C Villaruz, X Wang, E M Bertino, et al.
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Cancer Immunology, Immunotherapy : CII|July 31, 2020
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancerMingjia Li, Daniel Spakowicz, Songzhu Zhao, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2021
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survivalTyler C Haddad, Songzhu Zhao, Mingjia Li, et al.
Journal of Cancer Research and Clinical Oncology|September 7, 2022
Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survivalAbdul Miah, Gabriel Tinoco, Songzhu Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Pancreas|April 18, 2013
Consensus guidelines for the management and treatment of neuroendocrine tumorsPamela L Kunz, Diane Reidy-Lagunes, Lowell B Anthony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or LeptomeningesLaura Q M Chow, Fabrice Barlesi, Erin M Bertino, et al.
The Journal of Biological Chemistry|April 10, 1999
Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion moleculesC W Rittershaus, L J Thomas, D P Miller, et al.
Pageof 7